Leila Alland, newly appointed Chief Medical Officer of Cardiff Oncology, Inc., filed an initial statement of beneficial ownership with the SEC on October 27, 2026, reporting no securities beneficially owned as of the event date of October 23, 2026.

Key Highlights

  • Reporting person: Leila Alland, identified as Chief Medical Officer of Cardiff Oncology, Inc.
  • Event date: The date of the event requiring the statement is October 23, 2026.
  • Filing date: The form was signed and filed on October 27, 2026.
  • No securities held: The filing states "No securities are beneficially owned" in both the non-derivative and derivative securities tables.
  • Issuer: Cardiff Oncology, Inc., trading on NASDAQ:CRDF.

Cardiff Oncology CMO Alland Reports Zero Initial Holdings

Cardiff Oncology, Inc. (NASDAQ:CRDF) received an initial beneficial ownership statement from Leila Alland, who the filing identifies as the company's Chief Medical Officer. The filing, submitted pursuant to Section 16(a) of the Securities Exchange Act of 1934, covers the event date of October 23, 2026, and was signed on October 27, 2026.

According to the filing, both Table I, covering non-derivative securities, and Table II, covering derivative securities such as puts, calls, warrants, options, and convertible securities, are left blank. The explanation of responses section states explicitly: "No securities are beneficially owned." This indicates that as of the triggering event date, Alland held no direct or indirect beneficial ownership of Cardiff Oncology securities in either category.

The filing lists Alland's address as c/o Cardiff Oncology, Inc., 11055 Flintkote Avenue, San Diego, California 92121. The form was filed by one reporting person and does not reflect any amendment to a prior filing, as no original filing date is indicated in the amendment field.

What Was Disclosed

Leila Alland filed a Form 3 as Chief Medical Officer of Cardiff Oncology, Inc. (NASDAQ:CRDF), reporting that as of October 23, 2026, she beneficially owned no non-derivative or derivative securities of the company.